The focus of the industry on living human beings and the strict regulations that it imposes provide unique considerations for business leaders. These characteristics also make the industry a natural incubator for technological innovation, resulting in significant breakthroughs that have increased agricultural yields, created biofuels and led to life-saving pharmaceutical products.
Biotech startups have a variety of options for revenue generation strategies, with most opting for a technology-based partnership or an asset creation https://genotec-frankfurt.de/top-5-simple-virtual-deal-software-for-beginners/ and out-licensing strategy. Technology partnering can generate more revenue and reduce financial risk, while asset creation and outlicensing strategies can yield more returns. A growing number of biotechs at the research stage employ the hybrid approach, which combines both strategies.
If you choose to go with a product-oriented strategy can reap commercial success when they are able to get their pipelines to the right stage, and attract a big pharmaceutical partner or investor with deep pockets. This could be a costly option. It is essential to consider the balance between opportunistic strategies in taking advantage of outside resources and the proper scientific decision-making regarding domestic projects.
The “platform” model is a different option to generate revenue. It’s a lower-cost option than the product-oriented development however it carries significant risk. In this model biotechs have the ability to develop their own platform technology prior to teaming with pharma giants to create a range of drug discovery projects aimed at specific diseases (i.e. disease x is a biological condition that causes). This is the strategy Advinus Therapeutics and a few others have adopted.
(0)